Naturally Occurring Proteasome Inhibitors from Mate Tea (Ilex paraguayensis) Serve as Models for Topical Proteasome Inhibitors  by Arbiser, Jack L. et al.
Naturally Occurring Proteasome Inhibitors from Mate Tea
(Ilex paraguayensis) Serve as Models for Topical Proteasome
Inhibitors
Jack L. Arbiser, Xing-Cong Li,w Chowdhury Fiaz Hossain,w Dale G. Nagle,w David M. Smith,z Paul Miller,
Baskaran Govindarajan, Josh DiCarlo, Kristin R. Landis-Piwowar,z and Q. Ping Douz
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA; wDepartment of Pharmacognosy and National Center for Natural
Products Research, RIPS, School of Pharmacy, University of Mississippi, Mississippi, USA; zThe Prevention Program, Barbara Ann Karmanos Cancer Institute,
and Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan, USA
Proteasome inhibitors have emerged as a clinically important therapy for neoplastic disease, with velcade, an
organoboron compound used extensively in multiple myeloma. Recently, ()-epigallocatechin gallate has been
found to be a potent inhibitor of the proteasomal chymotrypsin-like activity. Other compounds that inhibit an-
giogenesis and are active as chemopreventive agents, such as curcumin, also inhibit proteasome activity. We have
screened natural product extracts using ras-transformed endothelial cells (SVR cells) as a bioassay, and found that
extracts of mate tea (Ilex paraguayensis) inhibit the growth of these endothelial cells. The extract was fractionated
and found to have novel cinnamate esters that inhibit proteasome activity. Based upon the structures of the
compounds isolated from mate tea, we examined synthetic analogs of these compounds for proteasome activity.
Cinnamic acid amides had no inhibitory activity against proteasomes, whereas cinnamate esters displayed the
activity. Based upon these ﬁndings, preclinical and clinical trials of topical cinnamate esters as proteasome in-
hibitors are warranted for psoriasis and other inﬂammatory disorders.
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Plant extracts are a major source of chemopreventive, an-
tiangiogenic, and antitumor agents. These include potent
agents that are present in small quantities, as well as com-
pounds that form a major portion of human diets. Intensive
investigation has identified a class of dietary available ma-
terials including green and black tea (Camelia sinensis), tur-
meric (Curcuma longa), and other agents that have been
found to have chemopreventive and antitumor activities in
experimental animals (Rao et al, 1995; Arbiser et al, 1998;
Thaloor et al, 1998). Systems in which these agents have
prevented the development of malignancy include the skin,
oral cavity, forestomach, duodenum, colon, breast, and
prostate (Huang et al, 1991, 1994; Singletary et al, 1998;
Elmets et al, 2001; Gupta et al, 2001). The mechanisms
through which these compounds prevent the development
of malignancy are not completely understood. The lack of
mechanism makes isolation and rational design of synthetic
congeners difficult, as the structural features required for
structure–function relationships are difficult to determine
without adequate in vitro assays.
We developed immortalized and transformed endothelial
cells through the sequential introduction of a temperature-
sensitive SV40 large T antigen and oncogenic H-ras into
murine microvascular endothelium (Arbiser et al, 1997).
These cells have proven extremely valuable in elucidating
mechanisms of the angiogenic switch (Klafter and Arbiser,
2000) (Arbiser, 2004). We now use ras-transformed end-
othelial cells (SVR cells) as a screening tool to isolate nat-
urally occurring compounds that may have antitumor or
antiangiogenic activities, or both (Arbiser et al, 1998, 1999).
Using this assay, we partially purified extracts from the plant
Ilex paraguayensis, which is consumed as a beverage in
large quantities in South America (Anghileri and Thouvenot,
2000). These extracts were chemically characterized and
found to contain caffeoyl esters of quinic acid. One of these
fractions was found to be 3,5-dicaffeoylquinic acid (3,5-
DCQ), which inhibits the chymotrypsin-like activity of a pu-
rified 20S proteasome and 26S proteasome in Jurkat T cell
extracts. 3,5-DCQ treatment of intact Jurkat T cells caused
growth arrest in the G2/M phase of the cell cycle. In
contrast, fraction T-2, identified as 5-caffeoylquinic acid (ne-
ochlorogenic acid) (5-CQ), contains much less proteasome-
inhibitory activity and fails to induce G2/M arrest in Jurkat T
cells. This finding suggests that proteasome activity may
depend on the number of cinnamate moieties. A cinnamate
tetraester (pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydro-
xyhydrocinnamate), PTTC) was tested and found to have
activity against proteasomes. This compound and its de-
rivatives may be useful in the topical and/or systemic treat-
ment of psoriasis.
Abbreviations: 5-CQ, 5-caffeoylquinic acid (neochlorogenic acid);
3,4-DCQ, 3,4-dicaffeoylquinic acid; 3,5-DCQ, 3,5-dicaffeoylquinic
acid; [()-EGCG], epigallocatechin gallate; PTTC, pentaerythritol
tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate)
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Results
Aqueous filtered extract of mate tea exerted a strong in-
hibitory effect on SVR endothelium. In order to determine
the component of mate tea responsible, the aqueous ex-
tract was fractionated by HPLC, and the ability of the frac-
tions to inhibit SVR cell proliferation was assessed. The
fractions that showed the most potent inhibitory effects
were fractions T-2, T-5, and T-6. The structures of T-2, T-5,
and T-6 were elucidated by proton NMR and mass spec-
troscopy (Fig 1). Fraction T-2 was found to be 5-CQ (ne-
ochlorogenic acid), fraction T-5 was found to be 3,5-DCQ,
and fraction T-6 was found to be 3,4-dicaffeoylquinic acid
(3,4-DCQ). The NMR spectra of the compounds are shown
below.
5-CQ14 (T-2; neochlorogenic acid) 1H NMR (CD3OD, 400
MHz): d 7.58 (1H, d, J¼ 15.9 Hz, H-70), 7.05 (1H, d, J¼1.2
Hz, H-20), 6.94 (1H, dd, J¼ 8.2, 1.5 Hz, H-60), 6.78 (1H, d,
J¼8.2 Hz, H-50), 6.31 (1H, d, J¼15.9 Hz, H-80), 5.37 (1H, br
d, J¼4.8 Hz, H-5), 4.18 (1H, m, H-3), 3.66 (1H, dd, J¼8.6,
3.2 Hz, H-4), 2.17 (3H, m, H-6ax, H-6eq, H-2eq), 1.97 (1H,
dd, J¼13.2, 10.4 Hz, H-2ax); 1C NMR (CD3OD, 100 MHz): d
178.4 (C, C-7), 169.2 (C, C-90), 149.5 (C, C-40), 147.0 (CH, C-
70), 146.8 (C, C-30), 128.1 (C, C-10), 123.0 (CH, C-60), 116.6
(CH, C-50), 115.9 (CH, C-20), 115.2 (CH, C-80), 75.5 (C, C-1),
75.0 (CH, C-4), 73.2 (CH, C-5), 68.3 (CH, C-3), 41.7 (CH2, C-
2), 36.8 (CH2, C-6). HRESIMS m/z 377.0807 [MþNa]þ
(calculated for C16H18O9Na, 377.0843).
3,5-DCQ14 (T-5) 1H NMR (CD3OD, 400 MHz): d 7.62 (1H, d,
J¼16.0 Hz, H-70 or H-700), 7.58 (1H, d, J¼ 16.0 Hz, H-70 or
H-700), 7.07 (2H, br s, H-20,-200), 6.97 (2H, m, H-60, H-600), 6.79
(1H, d, J¼8.0 Hz, H-50, H-500), 6.35 (1H, d, J¼ 16.0 Hz, H-80
or H-800), 6.27 (1H, d, J¼ 16.0 Hz, H-80 or H-800), 5.44 (1H, m,
H-3), 5.40 (1H, br d, J¼5.9 Hz, H-5), 3.99 (1H, dd, J¼ 7.4,
3.1 Hz, H-4), 2.34-2.15 (4H, m, H-2, H-6); 13C NMR (CD3OD,
100 MHz): d 177.5 (C, C-7), 168.5 (C, C-90 or C-900), 168.3 (C,
C-90 or C-900), 149.7 (2C, C-40, C-400), 147.4 (CH, C-70 or C-
700), 147.2 (CH, C-70 or C700), 146.9 (2C, C-30, C-300), 128.0
(2C, C-10, C-100), 123.2 (CH, C-60 or C-600), 123.1 (CH, C-60 or
C-600), 116.6 (2CH, C-50, C-500), 115.7 (1C each, d, C-200),
115.5 (1C each, d, C-20), 115.4 (1C each, d, C-800), 115.2 (1C
each, d, C-80), 74.8 (C, C-1), 72.6 (CH, C-5), 72.2 (CH, C-3),
70.7 (CH, C-4), 37.7 (CH2, C-2), 36.1 (CH2, C-6). HRESIMS
m/z 539.1160 [MþNa]þ (calcd for C25H24O12Na,
539.1116).
3,4-DCQ14 (T-6) 1H NMR (CD3OD, 400 MHz): d 7.60 (1H, d,
J¼ 15.9 Hz, H-70or H-700), 7.52 (1H, d, J¼15.9 Hz, H-70 or
H-700), 7.03 (1H, br s, H-20 or H-200), 7.01 (1H, br s, H-20 or H-
200), 6.91 (2H, m, H-60, H-600), 6.75 (1H, d, J¼ 8.0 Hz, H-50,-
500), 6.29 (1H, d, J¼ 15.9 Hz, H-80 or H-800), 6.20 (1H, d,
J¼ 15.9 Hz, H-80 or H-800), 5.64 (1H, m, H-3), 5.14 (1H, dd,
J¼ 9.0, 2.6 Hz, H-4), 4.39 (1H, m, H-5), 2.32-2.11 (4H, m, H-
2, H-6); 13C NMR (CD3OD, 100 MHz): d 176.8 (C, C-7), 168.7
(C, C-90 or C-900), 168.4 (C, C-90or C-900), 149.7 (2C, C-40, C-
400), 147.7 (2CH, C-70,700), 146.8 (2C, C-30, C-300), 127.7 (2C,
C-10, C-100), 123.3 (2CH, C-60, C-600), 116.6 (2CH, C-50, C-
500), 115.3 (2CH, C-20, C-200), 114.8 (2CH, C-80, C-800), 76.3
(C, C-1), 75.8 (CH, C-4), 69.4 (CH, C-5), 69.1 (CH, C-3), 39.4
(CH2, C-2), 38.4 (CH2, C-6).
Inhibition of puriﬁed 20S proteasome The quinic acid
esters resemble the proteasome inhibitor ()-epigallocate-
chin gallate [()-EGCG] in that they contain hydroxylated
aromatic carboxylic acids esterified to a polyhydroxylated
aliphatic ring (Fig 2). Based upon this similarity, and the
previous finding that EGCG is an inhibitor of proteasomes
Figure1
Chemical structures of proteasome in-
hibitors isolated from mate tea.
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(Ren et al, 2000; Nam et al, 2001) (ref. 15 is not related to
EGCG as a proteasome inhibitor), the ability of fractions T-2,
T-5, and T-6 to inhibit proteasome function was assessed.
To determine the ability of quinic acid esters to inhibit pro-
teasome activity, a fluorescent substrate activity assay was
performed with purified 20S proteasome. EGCG (Sigma
Chemical Company, St Louis, Missouri) was used as a
positive control for proteasome inhibition. To ensure com-
plete inhibition of the proteasome, we used 100 mM EGCG.
The compound 3,5-DCQ was tested against proteasome
activity in three different concentrations: 20, 100, and 200 mg
per mL, which correspond to 37, 183, and 366 mM,
respectively (Fig 3). The IC50 value for 3,5-DCQ was de-
termined to be approximately 64 mM. In contrast,
neochlorogenic acid was found to be much weaker, with
an IC50 value of  564 mM for the purified 20S proteasome
(Fig 3). The potency of fraction T6 (3,4-DCQ) was between
that of 3,5-DCQ and neochlorogenic acid: at 100 mM, frac-
tions T-5, T-6, and T-2 inhibited the proteasomal chymo-
trypsin-like activity by 60%, 40%, and 21%, respectively.
These data suggest that 3,5-DCQ has the greatest protea-
some-inhibitor activity in all the structurally related sub-
stances tested (Fig. 4).
Inhibition of proteasome activity in Jurkat cell lysa-
tes We then tested the abilities of 3,5-DCQ and ne-
ochlorogenic acid to inhibit the 26S proteasome activity in
Jurkat cell extracts. We found that 3,5-DCQ at 20 mg per mL
(37 mM) inhibited the proteasome activity by  50%, and at
100 mg per mL (183 mM) inhibited the proteasome activity by
 85%, which was almost as potent as 100 mM EGCG. In
this assay, neochlorogenic acid (5-CQ) was also able to in-
hibit the proteasome activity (  30% at 20 mg per mL or
56 mM and  75% at 100 mg per mL or 282 mM), although
its potency was weaker than that of 3,5-DCQ. These data
further demonstrate that 3,5-DCQ is able to inhibit the
chymotrypsin-like activity of the 26S proteasome.
3,5-DC induces G2/M block in tumor cells To study
whether the proteasome-inhibitory potencies of 3,5-DCQ
and neochlorogenic acid are associated with growth-inhib-
itory activity in vivo, we treated Jurkat T cells with each
compound 2 or 20 mg per mL for 24 h. After treatment, the
cells were harvested and assayed by flow cytometry. 3,5-
DCQ at 2 mg per mL produced a very slight arrest of Jurkat
cells in the G2/M phase of the cell cycle, whereas 20 mg per
mL increased the G2/M population by nearly 10%. In con-
Figure 2
Effect of mate tea-derived compounds on
proteasome function in vitro and in vivo.
(A) Effect of 3,5-dicaffeoylquinic acid (3,5-
DCQ) (Q) on proteasome function in vitro
compared with neochlorogenic acid (Neo)
(C). (B) Effect of 3,5-DCQ and Neo on pro-
teasome function in vivo proteasome func-
tion. (C) Effect of 3,5-DCQ on proteasome
function in vitro compared with Neo on cell
cycle progression in Jurkat cells.
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trast, neochlorogenic acid at the same concentrations had
no effects. These data suggest that 3,5-DCQ inhibits the
proteasome in intact tumor cells, resulting in G2/M arrest.
Discussion
Controlled protein degradation plays a major role in the
regulation of multiple genes, including transcriptional acti-
vators, oncogenes, and tumor suppressor genes (Hershko
et al, 2000). An organoboron compound, velcade (PS-341,
bortezomib), has entered the clinic for the treatment of
multiple myeloma and other malignancies, based upon ev-
idence that constitutive activation of NFkB is required for
tumorigenesis (Richardson et al, 2002).
Other drugs may interact with the NFkB/IkB system to
explain their effects. Glucocorticoids, which are the main-
stay of anti-inflammatory activities, as well as first-line
treatment for several hematopoietic malignancies, including
multiple myeloma, also influence NFkB/IkB activation by
inducing IkB protein. Glucocorticoids, however, have other
undesirable effects not attributable to proteasome inhibi-
tion, such as atrophy of connective tissue and muscle. A
recent study of an animal model of psoriasis, derived from
transplantation of psoriatic human skin to an immunocom-
promised mouse, showed that systemic administration of a
proteasome inhibitor caused regression of psoriasis (Zollner
et al, 2002). Thus, proteasome inhibition is a valid target for
human psoriasis.
Topical therapies are the mainstay of human psoriasis
treatment. The most common therapy for psoriasis is top-
ical glucocorticoids (Wrone-Smith and Nickoloff, 1996;
Stern, 1997; Lebwohl, 2004; Nickoloff and Nestle, 2004).
These drugs have anti-inflammatory effects in psoriasis, but
are associated with side effects. Prominent among these
side effects are dermal atrophy, due to the known inhibitory
effect of glucocorticoids on collagen synthesis and depo-
sition. This often necessitates discontinuation of therapy.
Other topical agents include retinoids and vitamin D deriv-
atives. All of these are potentially irritating and less effective
than topical glucocorticoids. Thus, more effective therapies
with novel mechanisms of activity are needed in psoriasis.
Velcade is the only specific proteasome inhibitor cur-
rently used in humans. Other chemopreventive agents,
however, such as curcumin and EGCG, have proteasome
inhibitory activity (Nam et al, 2001; Jana et al, 2004). We
have previously demonstrated that curcumin has anti-
angiogenic activity in vivo, and curcumin ointments have
been shown to have benefit in human psoriasis (Arbiser
et al, 1998). Curcumin is a dimer of two cinnamoyl moieties
fused to a middle carbon, whereas EGCG is an ester of the
polyphenol catechin, with gallic acid (a hydroxylated ben-
zoic acid). Thus, the requirements for proteasome-inhibitory
activity are not fully understood. Upon fractionation of an-
tiangiogenic components of mate tea, we found that the
presence of two cinnamate esters was more potent as a
proteasome inhibitor than a single ester. One possibility is
that the difference between the monoester (caffeoylquinic
acid) and the 3,5-diester is simply that of hydrophobicity. In
order to make a topically available agent, several criteria
must be met. First, the agent must be lipophilic. Second, it
should not be allergenic. Attempts to make an ointment
using EGCG have not been successful due to irritation.1
Unsaturated cinnamates have been found to cause allergic
reactions in some individuals (Hausen et al, 1992). We thus
chose a saturated cinnamate that is highly lipophilic and has
a known human safety record as a candidate for treatment
of human skin. We found that PTTC, a commercially avail-
able antioxidant, fulfilled the criteria of having multiple
cinnamoyl ester groups and appropriate hydrophobicity.
PTTC is extensively used in industrial processes, and it has
not been shown to be carcinogenic, or toxic orally to rats
(LD5045000 mg per kg in the rat), or dermally to rabbits
(LD5043160 mg per kg in the rabbit) (Material Safety Data
Sheet, Great Lakes Chemical Corporation—Durad AX32,
MSDS number 00771). Thus, our study of mate tea deriv-
atives suggests that proteasome inhibitors can be synthe-
sized by varying the alcohol as well as producing multiple
ester groups. The development of polycinnamate esters as
proteasome inhibitors may lead to the development of top-
ical proteasome inhibitors, which may be used in inflam-
matory and neoplastic disorders, without the side effects of
topical glucocorticoids.
Materials and Methods
Preparation of mate tea extracts Powdered mate tea (Chimarrao
Laranjeiras Puraerva, Cascavel, Brazil) was supplied by Glenn and
Figure 3
Effect of pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhy-
drocinnamate) on proliferation of SVR cells. Note that the inhibition
of endothelial cell proliferation is concentration dependent.
Figure 4
Pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinna-
mate) (PTTC) inhibits chymotrypsin-like proteasome inhibitor. Note
that PTTC has inhibitory activity of the proteasome at high doses.
Epigallocatechin gallate is used as a positive control.
1D. Alberts, personal communication.
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Lynn Cohen (Atlanta, Georgia). Mate tea (100 g) was extracted by
boiling in 500 mL water for 30 min. PTTC was obtained from Ald-
rich Chemical Co (St Louis, Missouri). Once cool, the crude aque-
ous extract was first filtered through a 0.45 mm filter and further
filtered to exclude materials of greater than 3000 MW.
The filtered aqueous extract was lyophilized to a dry powder,
which was dissolved in distilled water and analyzed by HPLC, and
five fractions were collected. HPLC fractions were lyophilized.
Each fraction was reconstituted into 10 mg per mL solutions, and
the ability to inhibit proliferation of SVR cells was tested.
Cell proliferation assays SVR cells (1  104) were plated for 24 h
in a 24-well plate. The medium was then changed to DMEM con-
taining purified extract at a concentration of 10 mg per mL. Cells
were exposed to the drug for 72 h and were counted with a Coulter
Counter (Coulter, Hialeah, Florida) according to the method of
LaMontagne et al (2000).
General spectroscopic and spectrometric methods The NMR
spectra were recorded in CD3OD on a Bruker DRX 400 spectro-
meter operating at 400 MHz for 1H and 100 MHz for 13C, running
gradients, and using residual solvent peaks as internal references.
The HRESIMS data were acquired on a Bruker BioAPEX 30es
(NCNPR, University of Mississippi).
Chemical characterization of mate tea components The HPLC
fractions were found to be 5-CQ (neochlorogenic acid), 3,5-DCQ,
and 3,4-DCQ, respectively. The 1H and 13C NMR spectroscopic
data for the compounds isolated by HPLC were identified as three
known quinic acid derivatives. The relative number of caffeoyl ester
groups in each metabolite was evident from the number of char-
acteristic ester carbonyl carbon resonances observed in the 13C
NMR spectrum of each compound. The 13C NMR spectrum of 5-
CQ contained one carbon resonance for the free carboxylic acid
(178.4 ppm for C-7) and one carbon signal for the single ester
carbonyl (169.2 ppm for C-90). The di-substituted nature of the two
dicaffeoylquinic acid derivatives was evident from the presence of
two separate ester carbonyl resonances in the 13C NMR spectrum
of 3,5-DCQ (168.5 for C-90, 168.3 ppm for C-900) and 3,4-DCQ
(168.7 for C-90, 168.4 for C-900). The substitution patterns of the
caffeoyl ester moieties were identified, based upon the character-
istic downfield chemical shifts (1 ppm or greater) of the oxygen-
bearing a-methine proton signals in the 1H NMR spectrum of each
of the caffeoyl-substituted quinic acid derivatives. Since all were
previously reported known compounds, a detailed structure elu-
cidation of each metabolite was not required. All 1H and 13C NMR
chemical shifts were identical to those previously published (not
14). In addition, the molecular compositions of 5-CQ (C16H18O9)
and 3,5-DCQ (C25H24O12) were confirmed by high-resolution ES-
IMS analysis of the sodium adducts of each compound, respec-
tively.
Inhibition of puriﬁed 20S proteasome activity by HPLC-puriﬁed
mate tea fractions The chymotrypsin-like activity of purified 20S
proteasome was measured as previously described (Nam et al,
2001). Briefly, purified prokaryotic 20S proteasome (0.5 mg) was in-
cubated with 20 mM fluorogenic peptide substrate, Suc–Leu–Leu–
Val–Tyr—AMC, for 30 min at 371C in 100 mL of assay buffer (50 mM
Tris-HCl, pH 7.5), with or without a mate tea fraction at indicated
concentrations. After incubation, production of hydrolyzed 7-amido-
4-methyl-coumarin (AMC) groups was measured using a multi-well
plate VersaFluor Fluorometer with an excitation filter of 380 nm and
an emission filter of 460 nm (Bio-Rad, Hercules, California).
Inhibition of proteasome activity in Jurkat T cell extracts by
HPLC-puriﬁed mate tea fractions Whole-cell extracts (20 mg) of
Jurkat T cells were incubated for 60 min at 371C with 20 mM of
fluorogenic peptide substrate Suc–Leu–Leu–Val–Tyr–AMC in 100
mL of the assay buffer, with or without a mate tea fraction at in-
dicated concentrations. The hydrolyzed AMC were quantified as
described above.
Flow cytometry Cell cycle analysis based on DNA content was
performed, as described previously (Nam et al, 2001). The cell
cycle distribution is shown as the percentage of cells containing
G1, S, G2, and M DNA judged by propidium iodide staining.
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